A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2018

At a glance

  • Drugs Crenigacestat (Primary)
  • Indications Adenoid-cystic-carcinoma; B cell lymphoma; Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Leiomyosarcoma; Liver cancer; Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 28 Jul 2018 Results (n=110) published in the Annals of Oncology.
    • 23 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
    • 23 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top